Stage 4 Cardiovascular-Kidney-Metabolic syndrome was associated with a 3.48-fold higher risk of all-cause mortality compared to Stage 0 among U.S. cancer survivors.
Cohort (n=2,598)
Yes
Does advanced cardiovascular-kidney-metabolic (CKM) syndrome increase the risk of all-cause, cardio-cerebrovascular, and cancer mortality in cancer survivors?
Advanced CKM syndrome is strongly and independently associated with increased all-cause, cardiovascular, and cancer mortality among cancer survivors, highlighting the need for integrated cardiometabolic and oncologic care.
Hazard Ratio: 3.48 (95% CI 2.62–4.63)
Absolute Event Rate: 53.7% vs 7.2%
p-value: p=<0.001
BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome reflects the interplay of metabolic dysfunction, chronic kidney disease (CKD), and cardiovascular disease (CVD). However, the prognostic implications of CKM syndrome stages in this population remain unclear. METHODS: Data were drawn from the fasting subsample of NHANES III (1988-1994) and NHANES 1999-2018. A total of 2598 cancer survivors aged ≥ 20 years were included. Cox proportional hazards models accounting for the complex survey design were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: During a median follow-up of 7.92 years (IQR: 4.00-12.58), 1165 all-cause deaths, 352 CCD deaths, and 350 cancer deaths occurred. In fully adjusted models, compared with Stage 0, Stage 4 was associated with 3.48-fold higher all-cause mortality (HR = 3.48; 95% CI 2.62-4.63), 7.77-fold higher CCD mortality (HR = 7.77; 95% CI 4.21-14.32), and 2.55-fold higher cancer mortality (HR = 2.55; 95% CI 1.52-4.28). Advanced CKM syndrome was associated with elevated risks of all-cause, and cancer mortality. Sensitivity analyses confirmed the robustness of these findings. CONCLUSION: Advanced CKM syndrome is independently associated with increased risk of all-cause, cardiovascular, and cancer mortality among U.S. cancer survivors.
Liu et al. (Mon,) conducted a cohort in Cancer survivors (n=2,598). Stage 4 Cardiovascular-Kidney-Metabolic (CKM) syndrome vs. Stage 0 CKM syndrome was evaluated on All-cause mortality (HR 3.48, 95% CI 2.62-4.63, p=<0.001). Stage 4 Cardiovascular-Kidney-Metabolic syndrome was associated with a 3.48-fold higher risk of all-cause mortality compared to Stage 0 among U.S. cancer survivors.